Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 25, 2018. The document serves as a transaction notification regarding share allocations for Independent Non-Executive Directors for the service period of April 1, 2018, to June 30, 2018.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific director share transactions.
| Director | Instrument | Volume | Price |
|---|---|---|---|
| Sir Philip Hampton | Ordinary Shares | 2,809.891 | £15.57 |
| Mr Vindi Banga | Ordinary Shares | 461.625 | £15.57 |
| Dr Vivienne Cox | Ordinary Shares | 341.201 | £15.57 |
| Ms Lynn Elsenhans | ADSs | 1,203.681 | $41.34 |
| Dr Laurie Glimcher | ADSs | 1,329.780 | $41.34 |
| Dr Jesse Goodman | ADSs | 470.009 | $41.34 |
| Ms Judy Lewent | ADSs | 515.863 | $41.34 |
| Mr Urs Rohner | Ordinary Shares | 461.625 | £15.57 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports routine compliance transactions for director compensation.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are described as "Acquisition of notional Ordinary Shares" or "notional ADSs" under share allocation arrangements.
Investor Verification Checklist
- Verify the total number of shares/ADSs allocated to the board of directors for the Q2 2018 period.
- Confirm the exchange rate implied between the Ordinary Share price (£15.57) and ADS price ($41.34) at the time of transaction.
- Review the company's annual report (Form 20-F) for the full context of director remuneration policies.